INCY - Goldman Sachs cuts Incyte to hold cites Jakafi outlook uncertainty
2023-11-21 14:50:50 ET
More on Incyte
- Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript
- Incyte Corporation 2023 Q3 - Results - Earnings Call Presentation
- Incyte: One Of The Most Undervalued Pharmaceuticals
- Incyte Q3 2023 Earnings Preview
- Incyte says study evaluating efficacy of ruxolitinib cream in children met primary endpoint
For further details see:
Goldman Sachs cuts Incyte to hold, cites Jakafi outlook uncertainty